Filing Flows

Filing Flows › ArriVent BioPharma (AVBP) › Who owns the stock

Who owns ArriVent BioPharma (AVBP) stock

146 funds reported ArriVent BioPharma (AVBP) shares in their latest 13F filings, worth $1.6B in all. The largest holder is Suvretta Capital Management, LLC ($157M). Last quarter 96 funds added to their stakes and 41 cut them.

Largest holders of AVBP (13F)Largest holders of AVBP (13F)Suvretta Capital Management, LLC$157MInfinitum Asset Management, LLC$154MHhlr Advisors$136MBlackRock$113MOrbimed Advisors LLC$105MFMR LLC$96.5MOctagon Capital Advisors LP$68.5MVanguard Capital Management LLC$61.7MSofinnova Investments$58.9MState Street$58.8M

Largest holders (13F)

FundSharesValueChangeQuarter
Suvretta Capital Management, LLC4,515,531$157Mincrease2026-06-30
Infinitum Asset Management, LLC4,438,384$154Mincrease2026-06-30
Hhlr Advisors3,929,117$136Munchanged2026-06-30
BlackRock3,250,396$113Mincrease2026-06-30
Orbimed Advisors LLC3,027,328$105Munchanged2026-06-30
FMR LLC2,778,959$96.5Mdecrease2026-06-30
Octagon Capital Advisors LP1,971,054$68.5Munchanged2026-06-30
Vanguard Capital Management LLC1,774,873$61.7Mincrease2026-06-30
Sofinnova Investments1,696,752$58.9Munchanged2026-06-30
State Street1,692,986$58.8Mincrease2026-06-30
Vivo Capital, LLC1,682,097$58.4Mincrease2026-06-30
Novo Holdings A/S1,500,000$52.1Mdecrease2026-06-30
General Catalyst Group Management, LLC1,494,786$51.9Munchanged2026-06-30
Vanguard Group1,869,266$37.6Mdecrease2025-12-31
Logos Global Management LP1,000,000$34.7Mincrease2026-06-30

ArriVent BioPharma's latest quarter

ArriVent BioPharma, Q3 2026: revenue $5.0M, operating margin -867.5%, net loss $40.3M, operating cash flow −$40.7M. The chart follows the revenue to costs, profit and cash.

Questions

Who owns the most AVBP stock?

By the latest 13F filings: Suvretta Capital Management, LLC ($157M); Infinitum Asset Management, LLC ($154M); Hhlr Advisors ($136M); BlackRock ($113M); Orbimed Advisors LLC ($105M).

What is the short interest in AVBP?

6,806,605 shares were sold short at the 2026-10-15 settlement, -19.46% of the float.

Open the interactive view →

Updated Nov 9, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.